$LAB
STANDARD BIOTOOLS INC.

2023 Q4 Form 10-Q Financial Statement

#000095017023060385 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $28.19M $25.37M
YoY Change 4.32% -1.09%
Cost Of Revenue $14.83M $14.21M
YoY Change -6.45% -13.47%
Gross Profit $13.36M $11.15M
YoY Change 19.61% 20.98%
Gross Profit Margin 47.39% 43.97%
Selling, General & Admin $21.35M $22.29M
YoY Change -10.66% -24.68%
% of Gross Profit 159.87% 199.86%
Research & Development $6.909M $6.370M
YoY Change -17.52% -26.36%
% of Gross Profit 51.73% 57.11%
Depreciation & Amortization $3.906M $3.980M
YoY Change 7.93% 10.49%
% of Gross Profit 29.24% 35.68%
Operating Expenses $28.26M $32.33M
YoY Change -12.44% -40.87%
Operating Profit -$14.91M -$21.17M
YoY Change -29.4% -27.06%
Interest Expense -$1.098M $1.223M
YoY Change -7.73% 16.59%
% of Operating Profit
Other Income/Expense, Net $2.546M $1.448M
YoY Change 66.73% -770.37%
Pretax Income -$19.94M -$20.95M
YoY Change -4.03% -30.5%
Income Tax -$162.0K $100.0K
% Of Pretax Income
Net Earnings -$19.78M -$21.00M
YoY Change -5.13% -28.64%
Net Earnings / Revenue -70.16% -82.77%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$0.25 -$0.27
COMMON SHARES
Basic Shares Outstanding 79.40M 78.96M shares
Diluted Shares Outstanding 79.15M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.9M $128.9M
YoY Change -30.7% -30.41%
Cash & Equivalents $51.70M $79.66M
Short-Term Investments $63.19M $49.20M
Other Short-Term Assets $3.127M $3.400M
YoY Change -26.91% -26.23%
Inventory $20.53M $21.93M
Prepaid Expenses
Receivables $19.66M $16.56M
Other Receivables $0.00 $0.00
Total Short-Term Assets $158.2M $170.7M
YoY Change -24.23% -25.45%
LONG-TERM ASSETS
Property, Plant & Equipment $24.19M $24.54M
YoY Change -5.71% -7.7%
Goodwill $106.3M $106.2M
YoY Change 0.06% 0.15%
Intangibles $1.400M $4.200M
YoY Change -88.89% -72.73%
Long-Term Investments
YoY Change
Other Assets $2.285M $2.390M
YoY Change -26.5% -23.37%
Total Long-Term Assets $164.9M $168.5M
YoY Change -9.17% -9.34%
TOTAL ASSETS
Total Short-Term Assets $158.2M $170.7M
Total Long-Term Assets $164.9M $168.5M
Total Assets $323.1M $339.3M
YoY Change -17.23% -18.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.236M $7.327M
YoY Change 16.7% -21.26%
Accrued Expenses $9.152M $10.20M
YoY Change 48.21% 47.51%
Deferred Revenue $11.61M $11.23M
YoY Change 7.55% -0.78%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $59.53M $5.000M
YoY Change 2757.9% 500.24%
Total Short-Term Liabilities $109.3M $51.80M
YoY Change 151.66% 12.2%
LONG-TERM LIABILITIES
Long-Term Debt $3.983M $59.60M
YoY Change -93.66% -6.71%
Other Long-Term Liabilities $1.065M $1.086M
YoY Change 10.82% -7.26%
Total Long-Term Liabilities $1.065M $1.086M
YoY Change 10.82% -7.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $109.3M $51.80M
Total Long-Term Liabilities $1.065M $1.086M
Total Liabilities $159.9M $159.8M
YoY Change -0.41% -4.0%
SHAREHOLDERS EQUITY
Retained Earnings -$1.001B -$981.0M
YoY Change 8.06% 8.37%
Common Stock $83.00K $82.00K
YoY Change 3.75% 3.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$148.1M -$131.7M
YoY Change
Total Liabilities & Shareholders Equity $323.1M $339.3M
YoY Change -17.23% -18.23%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$19.78M -$21.00M
YoY Change -5.13% -28.64%
Depreciation, Depletion And Amortization $3.906M $3.980M
YoY Change 7.93% 10.49%
Cash From Operating Activities -$14.06M -$11.42M
YoY Change -26.69% -53.6%
INVESTING ACTIVITIES
Capital Expenditures $78.00K $900.0K
YoY Change -89.67% -171.2%
Acquisitions
YoY Change
Other Investing Activities -$13.04M -$49.02M
YoY Change -131.8% -508.5%
Cash From Investing Activities -$13.12M -$49.93M
YoY Change -132.59% -565.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.003M -1.170M
YoY Change 271.48% 23300.0%
NET CHANGE
Cash From Operating Activities -14.06M -11.42M
Cash From Investing Activities -13.12M -49.93M
Cash From Financing Activities -1.003M -1.170M
Net Change In Cash -28.18M -62.52M
YoY Change -235.52% 350.43%
FREE CASH FLOW
Cash From Operating Activities -$14.06M -$11.42M
Capital Expenditures $78.00K $900.0K
Free Cash Flow -$14.14M -$12.32M
YoY Change -29.08% -47.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001162194
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34180
dei Entity Registrant Name
EntityRegistrantName
STANDARD BIOTOOLS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0513190
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Tower Place
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
266-6000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
LAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79395035
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79655000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
49195000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
84475000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
592000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16560000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17280000
CY2023Q3 us-gaap Inventory Net
InventoryNet
21927000
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3404000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4278000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
170741000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
208815000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24538000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31191000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33883000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2390000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3109000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4200000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12600000
CY2023Q3 us-gaap Goodwill
Goodwill
106225000
CY2022Q4 us-gaap Goodwill
Goodwill
106251000
CY2023Q3 us-gaap Assets
Assets
339285000
CY2022Q4 us-gaap Assets
Assets
390310000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7327000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7914000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10423000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3980000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3682000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11234000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10792000
CY2023Q3 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3637000
CY2022Q4 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3644000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10199000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6175000
CY2023Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
5000000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2083000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
51800000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43443000
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54975000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54615000
CY2023Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
4615000
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
8194000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1017000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1055000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31150000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34081000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3474000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3816000
CY2023Q3 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
11635000
CY2022Q4 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
14359000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1086000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
961000
CY2023Q3 us-gaap Liabilities
Liabilities
159752000
CY2022Q4 us-gaap Liabilities
Liabilities
160524000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000
CY2023Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82527000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79904000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79470000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79482000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
82000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
80000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
856926000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
847008000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1949000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1896000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-980976000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-926096000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3057000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
422000
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5803000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
563000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-131720000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339285000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
390310000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25367000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25646000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78152000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70927000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14213000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16426000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41059000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45043000
CY2023Q3 us-gaap Gross Profit
GrossProfit
11154000
CY2022Q3 us-gaap Gross Profit
GrossProfit
9220000
us-gaap Gross Profit
GrossProfit
37093000
us-gaap Gross Profit
GrossProfit
25884000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6370000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8486000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19039000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29957000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22292000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26340000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
66187000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
82061000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
1998000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
3412000
us-gaap Restructuring Charges
RestructuringCharges
5415000
us-gaap Restructuring Charges
RestructuringCharges
5102000
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1666000
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
9000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1666000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
3857000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
32326000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
38247000
us-gaap Operating Expenses
OperatingExpenses
92307000
us-gaap Operating Expenses
OperatingExpenses
120977000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21172000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29027000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55214000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95093000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1223000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1049000
us-gaap Interest Expense
InterestExpense
3469000
us-gaap Interest Expense
InterestExpense
3141000
CY2023Q3 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0
CY2022Q3 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
60081000
CY2023Q3 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0
CY2022Q3 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-13719000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1448000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4417000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-119000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20947000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30139000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54266000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172153000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-713000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
614000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2900000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20997000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29426000
us-gaap Net Income Loss
NetIncomeLoss
-54880000
us-gaap Net Income Loss
NetIncomeLoss
-169253000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79152000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79152000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78897000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78897000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78967000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78967000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77924000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77924000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20997000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29426000
us-gaap Net Income Loss
NetIncomeLoss
-54880000
us-gaap Net Income Loss
NetIncomeLoss
-169253000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-403000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-118000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-560000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-753000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-238000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
507000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-949000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-398000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-356000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-53000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1702000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21395000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29782000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54933000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-170955000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3148000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2466000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97153000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-36000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
326000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3114000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2375000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-223000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-113387000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-11000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3386000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
399000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20997000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-398000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-131720000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94596000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-89000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4042000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22113000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-88000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
497000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4663000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-63539000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1196000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-37454000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-5000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4494000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29426000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-356000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-62747000
us-gaap Net Income Loss
NetIncomeLoss
-54880000
us-gaap Net Income Loss
NetIncomeLoss
-169253000
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
60081000
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-13719000
us-gaap Share Based Compensation
ShareBasedCompensation
9648000
us-gaap Share Based Compensation
ShareBasedCompensation
13199000
lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
8400000
lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
8728000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
2874000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
2680000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
963000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
7239000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3526000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
597000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
628000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-224000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
165000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-677000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1123000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3258000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7810000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-749000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
83000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-484000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1501000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1366000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
5561000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
218000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2408000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4128000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5783000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29226000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70189000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55857000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
137302000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
91964000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
12000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2753000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3070000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33354000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-128372000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
225000000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
833000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
6838000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
12547000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
80000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
97000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5240000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
326000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
497000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
139000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
181000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5806000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231028000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-196000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-719000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1874000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31748000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29467000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80450000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61215000
us-gaap Interest Paid Net
InterestPaidNet
2171000
us-gaap Interest Paid Net
InterestPaidNet
1847000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
629000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
248000
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
226000
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
503000
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
739000
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
703000
CY2023Q3 us-gaap Inventory Net
InventoryNet
21927000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves; the carrying value of goodwill and other long-lived assets; and the potential outcome of uncertain tax positions that have been recognized in the Company’s consolidated financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company’s condensed consolidated financial statements.</span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the condensed consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.</span></p>
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
409000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
945000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11212000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
15245000
CY2023Q3 us-gaap Inventory Gross
InventoryGross
28689000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
33056000
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6762000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
11583000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16872000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14253000
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
111012000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
108393000
CY2023Q3 lab Number Of Additional Shares Issuable Under Make Whole Premium Maximum
NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum
2181036
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25367000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25646000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78152000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70927000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25367000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25646000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78152000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70927000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14700000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14600000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
9300000
lab Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
9400000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4669000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
10783000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5660000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3556000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
24668000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2900000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8900000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9200000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2867000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1407000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4274000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79655000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
795000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1015000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80450000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
17068000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
16866000
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55125000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53069000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33641000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29029000
CY2023Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
3054000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1612000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24538000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
5580000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1170000
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2710000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2795000
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
872000
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1174000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1261000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
4014000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10423000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000
CY2023Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
928000
CY2022Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
800000
CY2023Q3 lab Accrued Interest Current
AccruedInterestCurrent
1019000
CY2022Q4 lab Accrued Interest Current
AccruedInterestCurrent
318000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1780000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
349000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1062000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1443000
CY2023Q3 lab Uninvoiced Receipts Current
UninvoicedReceiptsCurrent
1766000
CY2022Q4 lab Uninvoiced Receipts Current
UninvoicedReceiptsCurrent
1078000
CY2023Q3 lab Accrued Warranties Current
AccruedWarrantiesCurrent
2111000
CY2022Q4 lab Accrued Warranties Current
AccruedWarrantiesCurrent
678000
CY2023Q3 lab Customer Advance Current
CustomerAdvanceCurrent
538000
CY2022Q4 lab Customer Advance Current
CustomerAdvanceCurrent
577000
CY2023Q3 lab Accrued Restructuring Current
AccruedRestructuringCurrent
281000
CY2022Q4 lab Accrued Restructuring Current
AccruedRestructuringCurrent
19000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
714000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
913000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10199000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6175000
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Capital Expenditures
ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures
22200000
CY2023Q3 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000
CY2022Q3 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
2700000
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
2600000
CY2023Q3 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
6900000
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
4200000
CY2023Q3 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
15300000
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
18000000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
64590000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
64892000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2030-04-30
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
contains an option to extend the lease
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
along with termination options
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
115623000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115628000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
138871000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
502000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
138369000
CY2023Q3 us-gaap Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery
DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000
CY2023Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
175910
CY2023Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
400000
CY2023Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
2.25
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
3056903
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5800000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6946000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7882000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.43
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2559000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1148000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.8
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9249000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1780000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2986000
CY2023Q3 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
4.05
lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne
P8Y3M18D
CY2023Q3 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue
278000
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
6263000
CY2023Q3 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
3.43
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2023Q3 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
1502000
CY2023Q3 us-gaap Share Price
SharePrice
2.9
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
3412000
us-gaap Restructuring Charges
RestructuringCharges
5415000
us-gaap Restructuring Charges
RestructuringCharges
5102000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3386000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4494000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9648000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13199000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2900000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25367000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25646000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78152000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70927000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
1998000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
3412000
us-gaap Restructuring Charges
RestructuringCharges
5415000
us-gaap Restructuring Charges
RestructuringCharges
5102000
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1666000
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
9000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1666000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
3857000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21172000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29027000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55214000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95093000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
2000000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
3400000
us-gaap Restructuring Charges
RestructuringCharges
5400000
us-gaap Restructuring Charges
RestructuringCharges
5100000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
4033000
us-gaap Restructuring Charges
RestructuringCharges
5415000
us-gaap Payments For Restructuring
PaymentsForRestructuring
7906000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
1542000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
1998000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-060385-index-headers.html Edgar Link pending
0000950170-23-060385-index.html Edgar Link pending
0000950170-23-060385.txt Edgar Link pending
0000950170-23-060385-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img186375141_0.jpg Edgar Link pending
lab-20230930.htm Edgar Link pending
lab-20230930.xsd Edgar Link pending
lab-ex31_1.htm Edgar Link pending
lab-ex31_2.htm Edgar Link pending
lab-20230930_cal.xml Edgar Link unprocessable
lab-20230930_def.xml Edgar Link unprocessable
lab-20230930_lab.xml Edgar Link unprocessable
lab-20230930_pre.xml Edgar Link unprocessable
lab-20230930_htm.xml Edgar Link completed
lab-ex32_1.htm Edgar Link pending
lab-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending